Rachel Okabe

2.9k total citations
22 papers, 2.0k citations indexed

About

Rachel Okabe is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Rachel Okabe has authored 22 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 11 papers in Molecular Biology and 11 papers in Genetics. Recurrent topics in Rachel Okabe's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Acute Myeloid Leukemia Research (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Rachel Okabe is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Acute Myeloid Leukemia Research (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Rachel Okabe collaborates with scholars based in United States, Germany and United Kingdom. Rachel Okabe's co-authors include D. Gary Gilliland, Benjamin H. Lee, Gerlinde Wernig, Michael G. Kharas, Thomas Mercher, Ross L. Levine, Mahnaz Paktinat, Maricel Gozo, Kira Gritsman and Fátima Al‐Shahrour and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Blood.

In The Last Decade

Rachel Okabe

22 papers receiving 2.0k citations

Peers

Rachel Okabe

HEMAT

GENET

ONCOL

RHEUM

Maricel Gozo United States

Margaret Nieborowska-Skorska United States

Sandra Moore United States

Jyoti Nangalia United Kingdom

J V Melo United Kingdom

Artur Słupianek United States

Eva Hellström‐Lindberg Sweden

Hui Hao-Shen Switzerland

Kimberly Hayes United States

Andrea Hoelbl‐Kovacic Austria

Maricel Gozo United States

Rachel Okabe

1.3k ×1.1

1.1k ×1.1

HEMAT

1.3k ×1.3

GENET

389 ×1.0

ONCOL

438 ×1.3

RHEUM

Citations per year, relative to Rachel Okabe Rachel Okabe (= 1×) peers Maricel Gozo

Countries citing papers authored by Rachel Okabe

Since Specialization

Citations

This map shows the geographic impact of Rachel Okabe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Okabe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Okabe more than expected).

Fields of papers citing papers by Rachel Okabe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Okabe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Okabe. The network helps show where Rachel Okabe may publish in the future.

Co-authorship network of co-authors of Rachel Okabe

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Okabe. A scholar is included among the top collaborators of Rachel Okabe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Okabe. Rachel Okabe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Okabe, Rachel, Alexandra Schurer, Meng Tong, et al.. (2022). Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. Clinical Cancer Research. 29(5). 943–956. 1 indexed citations

Tong, Meng, Boris Bartholdy, Rachel Okabe, et al.. (2019). PI3K alpha and delta promote hematopoietic stem cell activation. JCI Insight. 4(13). 30 indexed citations

Gritsman, Kira, Haluk Yuzugullu, Thanh Von, et al.. (2014). Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. Journal of Clinical Investigation. 124(4). 1794–1809. 46 indexed citations

Tam, Winnie F., Patricia S. Hähnel, Andrea Schüler, et al.. (2012). STAT5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF2. Cancer Research. 73(1). 373–384. 26 indexed citations

Xiao, Nan, Kelly Morgan, Rachel Okabe, et al.. (2012). Hematopoietic stem cells lacking Ott1 display aspects associated with aging and are unable to maintain quiescence during proliferative stress. Blood. 119(21). 4898–4907. 33 indexed citations

Kvinlaug, Brynn T., Lars Bullinger, Mukundhan Ramaswami, et al.. (2011). Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias. Cancer Research. 71(12). 4117–4129. 37 indexed citations

Wernig, Gerlinde, Michael G. Kharas, Ann Mullally, et al.. (2011). EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 26(4). 720–727. 14 indexed citations

Kharas, Michael G., Christopher J. Lengner, Fátima Al‐Shahrour, et al.. (2010). Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. DSpace@MIT (Massachusetts Institute of Technology). 2 indexed citations

Mullally, Ann, Steven Lane, Brian Ball, et al.. (2010). Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells. Cancer Cell. 17(6). 584–596. 285 indexed citations

10.

Kharas, Michael G., Christopher J. Lengner, Fátima Al‐Shahrour, et al.. (2010). Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nature Medicine. 16(8). 903–908. 269 indexed citations

11.

Hofmann, Inga, Elizabeth H. Stover, Dana E. Cullen, et al.. (2009). Hedgehog Signaling Is Dispensable for Adult Murine Hematopoietic Stem Cell Function and Hematopoiesis. Cell stem cell. 4(6). 559–567. 129 indexed citations

12.

Kharas, Michael G., Rachel Okabe, Maricel Gozo, et al.. (2009). Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood. 115(7). 1406–1415. 214 indexed citations

13.

Wernig, Gerlinde, Michael G. Kharas, Rachel Okabe, et al.. (2008). Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera. Cancer Cell. 13(4). 311–320. 305 indexed citations

14.

Wernig, Gerlinde, Michael G. Kharas, Dena S. Leeman, et al.. (2008). EXEL-8232, a Small Molecule JAK2 Inhibitor, Effectively Treats Thrombocytosis and Extramedullary Hematopoiesis in a Murine Model of Myeloproliferative Disease Induced by MPLW515L. Blood. 112(11). 3741–3741. 1 indexed citations

15.

Wernig, Gerlinde, Michael G. Kharas, Rachel Okabe, et al.. (2007). Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.. Blood. 110(11). 556–556. 10 indexed citations

16.

Rocnik, Jennifer L., Rachel Okabe, Jin‐Chen Yu, et al.. (2006). Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood. 108(4). 1339–1345. 105 indexed citations

17.

Wernig, Gerlinde, Thomas Mercher, Rachel Okabe, et al.. (2006). Expression of Jak2V617F causes a polycythemia vera–like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 107(11). 4274–4281. 364 indexed citations

18.

Millar, Lynnae K., Nicole Streiner, Sandra Y. Yamamoto, et al.. (2005). Early Placental Insulin-Like Protein (INSL4 or EPIL) in Placental and Fetal Membrane Growth1. Biology of Reproduction. 73(4). 695–702. 22 indexed citations

19.

Chen, Jing, Benjamin H. Lee, Ifor R. Williams, et al.. (2005). FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 24(56). 8259–8267. 72 indexed citations

20.

Baron, Rebecca M., Irvith M. Carvajal, Xiaoli Liu, et al.. (2004). Reduction of Nitric Oxide Synthase 2 Expression by Distamycin A Improves Survival from Endotoxemia. The Journal of Immunology. 173(6). 4147–4153. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact